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Abstract
Background: Castrate-resistant prostate cancer (CRPC) is a lethal condition in patients receiving androgen deprivation
therapy for prostate cancer (PC). Despite numerous studies showing the expression of HIF1a protein under normoxia in PC
cell lines, the role of this normoxic HIF1a expression in chemo-resistance and migration has not been investigated
previously. As no method is currently available to determine which tumors will progress to CRPC, the role of HIF1a in PC and
its potential for predicting the development of CRPC was also investigated.
Methods: The effect of HIF1a protein knockdown on chemo-resistance and migration of PC3 cells was assessed by cell
counting and Transwell assays, respectively. Translation efficiency of HIF1a mRNA was determined in PC cells using a HIF1a
59UTR-luciferase construct. Clinical outcomes were correlated following the staining of 100 prostate tumors for HIF1a
expression.
Results: The CRPC-like cell lines (PC3 and DU145) expressed more HIF1a protein than an androgen sensitive cell line
(LNCaP). Migration rate and chemo-resistance were higher in the PC3 cells and both were decreased when HIF1a expression
was reduced. Increased translation of HIF1amRNA may be responsible for HIF1a overexpression in PC3 cells. Patients whose
tumors expressed HIF1a had significantly decreased metastasis-free survival and the patients who were on androgen-
deprivation therapy had decreased CRPC-free survival on Kaplan-Meier analysis. On multivariate analysis HIF1a was an
independent risk factor for progression to metastatic PC (Hazard ratio (HR) 9.8, p = 0.017) and development of CRPC (HR
10.0, p = 0.021) in patients on androgen-deprivation therapy. Notably the tumors which did not express HIF1a did not
metastasize or develop CRPC.
Conclusions: HIF1a is likely to contribute to metastasis and chemo-resistance of CRPC and targeted reduction of HIF1a may
increase the responsiveness of CRPCs to chemotherapy. Expression of HIF1a may be a useful screening tool for
development of CRPC.
Citation: Ranasinghe WKB, Xiao L, Kovac S, Chang M, Michiels C, et al. (2013) The Role of Hypoxia-Inducible Factor 1a in Determining the Properties of Castrate-
Resistant Prostate Cancers. PLoS ONE 8(1): e54251. doi:10.1371/journal.pone.0054251
Editor: Irina U. Agoulnik, Florida International University, United States of America
Received August 22, 2012; Accepted December 10, 2012; Published January 16, 2013
Copyright:  2013 Ranasinghe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants 454322 (GSB), 566555 (GSB, AS) and 628390 (AS, OP, GSB) from the National Health and Medical Research Council of
Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: patelo@unimelb.edu.au
Introduction
Prostate cancer (PC) is the second most common cancer in men
worldwide and continues to impose a significant disease burden
and a growing worldwide healthcare problem. However, our
understanding of the mechanisms that contribute to the develop-
ment of PC is still limited [1]. Androgens and the androgen
receptor (AR) are important regulators of stimulation and survival
of prostate cancer cells. Androgen deprivation therapy (ADT) is
the mainstay of treatment for metastatic and locally advanced
prostate cancer. However, ADT eventually fails to maintain
prostate cancer suppression in a majority of men with this
condition.
Castrate-resistant prostate cancer (CRPC) is a lethal form of PC
that may progress and metastasize rapidly. On development of
CRPC, more than 84% of patients will have metastases [2]. Few
biomarkers for prediction of CRPC have been described [3], [4],
and currently there is no universal consensus on identifying which
patients with PC will progress to CRPC. Furthermore the
mechanisms resulting in the development and progression of
CRPC remain poorly understood in part because of the limited
availability of cell lines which closely model CRPC. The two
widely used PC cell lines PC3 and DU145 are not considered as
fully representative of CRPC cells since they were not isolated
from prostate cancers that had relapsed after androgen depriva-
tion therapy, and since they express little [5] if any AR [6],
whereas AR is often over-expressed in CRPC tumors. However as
PC3 and DU145 cells display some of the fundamental properties
of a CRPC tumor including high migration (metastasis), androgen-
independence and chemo-resistance similar to the CRPC cell line
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LNCaP C4-2 [7], and also share similar molecular properties,
including depletion/mutation of mitochondrial DNA, which have
been correlated with invasiveness and drug resistance [8], these
two cell lines are frequently referred to as CRPC cells [9], [10],
[11].
Hypoxia is a reduction in the normal concentration of tissue
oxygen which occurs in many diseases including cancer. A hypoxic
microenvironment within the prostate has been postulated to be
responsible for the promotion of secondary genetic alterations and
angiogenic stimulation, leading to a more aggressive cell pheno-
type and malignant progression [12]. The ability of cells to adapt
to hypoxia is dependent on a set of hypoxia-inducible transcription
factors (HIFs) which consist of a regulatory alpha (HIF1a) and a
constitutive beta subunit (HIF1b). HIFs bind to the core sequence
59-RCGTG-39 in target promoters and induce more than 200
functionally diverse genes involved in cell survival [13]. The
synthesis of HIF1a occurs via oxygen-independent mechanisms
but its degradation is oxygen-dependent and involves prolyl
hydroxylase, asparaginyl hydroxylase, the Von Hippel-Lindau
protein and the proteasomal system [13].
Although HIF1a is over expressed in a number of human
cancers [14], [15], the role of HIF1a in cancer progression is
unclear. High concentrations of HIF1a in renal and breast cancer
cell lines were shown to increase cancer cell survival, whereas in
ovarian cancer high HIF concentrations contributed to increased
apoptosis [13]. Dai and co-workers reported that acute hypoxia
increased HIF1a expression and the motility and invasive capacity
of three PC cell lines [16]. However, despite numerous studies
showing the presence of HIF1a expression in normoxia, and a
report that HIF1a signaling is upregulated in normoxic castration-
resistant LNCaP C4-2 cells as compared to the parental LNCaP
cells [17], the role of normoxic HIF1a expression is not well
documented, and therefore formed the basis of our current study.
Similarly, despite high HIF1a expression in PC tissues [14],
[18], [19], [20], [21], [22], [23], [24], its association with
prognosis is inconclusive [25], [24], [26], [27]. However the
consensus is that HIF1a is upregulated in prostate tumors [28],
[24] and is a potent tumor-induced shield against oxidative stress
or destruction by androgen deprivation, chemotherapy or
radiation cytotoxicity [29]. Currently no studies have reported
the relationships between HIF1a expression and the development
of CRPC. Therefore, we aimed to investigate the role of HIF1a in
the regulation of CRPC and to analyze its potential as a biomarker
for prediction of the development of CRPC.
Materials and Methods
In Vitro Studies
Cell culture. The three human prostate cancer cell lines
(PC3, DU145 and LNCaP) used in this study were generously
donated by A/Prof. Ian Davis, Ludwig Institute for Cancer
Research, Melbourne, and had been purchased from ATCC in
2009. Cell lines were cultured in RPMI 1640 medium (Invitrogen,
Mulgrave, Australia) supplemented with 8% FBS and 100 U/mL
penicillin. All cells were maintained at 37uC in a humidified
incubator with 95% air and 5% CO2. The hypoxia-treated cells
were cultured in the same way as the controls except that the gas
phase contained 94% nitrogen (N2), 5% CO2 and 1% O2, with
oxygen concentrations monitored and automatically adjusted by
an electronic oxygen controller (ProOx Model 110, Biospherix,
Redfield, NY).
Western blot analysis. Cells were washed once with ice-cold
phosphate-buffered saline (PBS) and lysed with 0.1–0.2 ml pre-
boiled sodium dodecyl sulphate (SDS) lysis buffer. Proteins were
separated by SDS-polyacrylamide gel electrophoresis, and trans-
ferred onto a Hybond-C Extra nitrocellulose membrane (GE
Healthcare, Rydalmere, Australia). HIF1a protein was detected
with a monoclonal mouse anti-human HIF1a antibody (1:1000,
BD Biosciences, North Ryde, Australia) followed by a secondary
goat anti-mouse horseradish peroxidase-conjugated antibody
(1:5000, Bio-Rad). As a loading control, blots were incubated
with a horseradish peroxidase (HRP)-conjugated rabbit anti-
GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Bands were visualized in a LAS 3000 Image Reader (Fujifilm,
Brookvale, Australia), with an ECL Advance Western Blotting
Detection Kit (GE Healthcare). Densitometric analysis of the
protein bands was performed with MultiGauge software (Fujifilm).
Proliferation assay. For measurement of basal levels of
proliferation, 26 105 cells were cultured in a 6 well petri-dish in
culture medium supplemented with FBS. Cells were washed with
PBS at 24 hours and cultured for a further 48 hours in serum free
medium. The cells which were to receive treatment were plated as
above, and the media was removed at 24 hours and supplemented
with FBS-free media before treatment with hydrogen peroxide
(H2O2), cobalt chloride, 5-fluorouracil (5-FU) or hypoxia (1% O2)
for 48 hours. Cells were counted using an automated cell counter
(CountessH, Invitrogen).
Migration/invasion Assays (Transwell Assay)
Prostate cancer cells were seeded at a density of 26105 cells in
250 ml per well of serum-free culture medium onto the upper
chamber of polyethylene terephthalate filter membranes coated
with fibronectin. The upper chambers were inserted into tissue-
culture wells and 750 ml serum-free culture medium was added to
the lower chamber. After incubation overnight at 37uC, non-
migratory cells on the surface of the upper membrane were
removed with a cotton swab, and cells that had migrated through
the membrane pores and invaded the underside of the membrane
were fixed with 90% methanol and stained with hematoxylin and
eosin. For quantitative assessment, the number of stained,
migrating cells was then counted under a microscope. Five low-
power fields per filter were counted on three separate occasions for
three independent experiments.
Stable HIF1a knock down in PC3 cells. Plasmids encoding
human HIF1a shRNA (MissionH clone numbers
TRCN0000003810 and TRCN0000010819, which encode a
hairpin-type siRNA) and a negative control plasmid (SHC002)
were purchased from Sigma-Aldrich (St. Louis, MO). Cells were
transfected with either a HIF1a shRNA plasmid or the negative
control plasmid using the NeonH transfection method (Invitrogen).
Briefly, 1 6 106 cells were trypsinized, washed with PBS, and
pelleted before resuspension in 100 ml Neon resuspension buffer.
HIF1a or control shRNA plasmid (5 mg) were added and mixed
well into the cell suspension prior to transfection. The transfected
cells were seeded in complete medium and selected with 1.0 mg/
ml puromycin (Sigma-Aldrich) for 7 days before further assays.
Knockdown of the HIF1a protein was demonstrated by Western
blotting, and by measurement of its downstream product, vascular
endothelial growth factor (VEGF), by enzyme-linked immunosor-
bent assay (ELISA).
Translation efficiency. To determine whether the 59UTR
of HIF1amRNA has any role in HIF1a overexpression in prostate
cells a reporter plasmid was constructed in which the entire
59UTR and 238 bp of the HIF1a promoter sequence was cloned
upstream of Firefly luciferase coding sequences in the pGL4.10
reporter plasmid. The reporter construct was transfected into
LNCaP and PC3 cells and the firefly luciferase activity driven by
the HIF1-UTR reporter vector and Renilla luciferase (pTK-Renilla
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control reporter vector) were determined following 24 hours of
incubation. Total mRNA was extracted from the transfected cells
and the quantity of luciferase mRNA was determined using Real
Time PCR. Luciferase mRNA in the cells transfected with the
empty pGL4 vector was used as the basal control. Translation
efficiency was calculated by dividing the Firefly luciferase activity
(proportional to luciferase protein) by the concentration of Firefly
luciferase mRNA. This ratio was further corrected for transfection
efficiency by taking into account the Renilla luciferase activity.
Clinical Outcome Studies
Human tissue samples. For the assessment of associations
between HIF1a expression and clinical outcomes, 100 human
prostate tumors from patients who had provided informed written
consent were collected following radical prostatectomy or trans-
urethral resection of the prostate (TURP) at our institution
between 2000 and 2011. All samples were obtained from the
Victorian Cancer Biobank and or the Department of Anatomical
Pathology at the Austin Hospital, Victoria, Australia. Approval for
the use of biological specimens and de-identified patient data for
this study was obtained from the Austin Health Human Research
Ethics Committee.
Immunohistochemistry. Paraffin-embedded tissue sections
were de-waxed in histolene and hydrated with decreasing ethanol
concentrations. Slides were rinsed in Tris-buffered saline/
Tween20 (TBST) and the antigens were retrieved by heating in
citric acid buffer (pH 6.0) in a microwave for 2 minutes on
medium high and 13 minutes on medium low. Slides were allowed
to cool and endogenous peroxidases in the specimens were blocked
by treatment with 3% hydrogen peroxide for 10 minutes in the
dark. Slides were washed in water, equilibrated in TBST buffer,
blocked with ultravision (Thermo Fisher Scientific) for 10 minutes
and stained for HIF1a using a HIF1a polyclonal antibody (1:100,
Santa Cruz Biotechnology, Santa Cruz, CA) at 4uC overnight.
After antibody incubation, slides were treated with a HRP-
conjugated secondary antibody (Dako) in the dark at room
temperature for 1 hour. Slides were washed with TBST following
5 minutes incubation with 3,39-diaminobenzidine (DAB) chromo-
gen (1 drop/ml of substrate buffer, Dako) to complete colour
development. Finally, slides were counterstained with hematoxylin
for 1 minute, washed in running water and Scott’s tap water for 1
minute each, dehydrated and cover slipped. The investigators
were blinded to the status of individual samples, and tumors were
divided according to the presence or absence of HIF1a rather than
weak or strong staining to reduce the inter-observer variation.
Outcomes. Distant metastases were defined by abnormalities
documented on bone-scan or computed tomography. CRPC was
defined as 2 consecutive rises of prostate-specific antigen (PSA)
from the PSA nadir. The time to development of distant metastasis
was measured from surgery, while the time to development of
CRPC, chemo-resistance and PC-specific death were measured
from the start of androgen deprivation. Pre-interventional PSA
was defined as PSA immediately prior to obtaining the tissue
sample, and T3 and T4 staging was defined as locally advanced
prostate cancer as in the 2002 American Joint Commission on
Cancer staging system [30].
Statistical analysis. Statistical analysis was performed under
the guidance of the statistical counseling service, University of
Melbourne, Australia. Pearson’s Chi-squared analysis and Fisher’s
exact tests were conducted using two-by-two tables (Gleason score,
HIF1a positivity, tumor stage and number of patients started on
androgen deprivation therapy) on SigmaStat software (Jandel
Scientific, San Rafael, CA) to test the association between the
patient characteristics and HIF1a expression. Univariate and
multivariate analysis were performed using Cox regression models
for all variables. In order to overcome the non-convergence of the
Cox regression model when analyzing for HIF1a positivity and
Gleason score (as there were no outcomes in the HIF1a negative
group and the low Gleason scores), these univariate and
multivariate analysis were calculated by Cox regression with
Firth’s penalized maximum likelihood method using R software,
(R foundation for Statistical Computing version 2.14.0). Survival
was calculated for each outcome using Kaplan-Meier curves with
log rank test on the SPSS statistical package (IBM SPSS version
17). Diagnostic test evaluations with sensitivity and specificity
analysis were performed using MedCalc statistical software
(MedCalc Software, Belgium http://www.medcalc.org/).
In vitro data are presented as means 6 SEM. Statistical
significance for single comparisons of normally distributed data
was determined by Student’s t test or for data that was not
normally distributed by Mann-Whitney rank sum test. For
multiple comparisons one-way ANOVAs followed by the Bonfer-
roni correction were performed. All statistics were analyzed with
the program SigmaStat (Jandel Scientific).
Results
HIF1a Expression Correlates with Migration Rate in PC
Cells
HIF1a protein expression was analyzed in androgen-sensitive
(LNCaP) and androgen-insensitive (PC3 and DU145) CRPC-like
cells. Basal HIF1a expression under normoxia was higher by
1266-fold and 1064-fold respectively in the CRPC-like cell lines
PC3 and DU145 as compared to androgen-sensitive LNCaP cells
(Figure 1A). Interestingly the observation that the basal growth
rate of LNCaP cells in serum-free conditions was much higher
than PC3 cells, which express more HIF1a, indicates that
increased expression of HIF1a does not necessarily lead to greater
proliferation (Figure 1B). To investigate the metastatic potential of
the PC cell lines, migration of the CRPC cell lines PC3 and
DU145 was compared to androgen-sensitive LNCaP cells using a
Transwell assay. The observation that migration of PC3 and
DU145 cells was 17766% and 215617% respectively of the value
for LNCaP cells (100%) (Figure 1C) indicated that overexpression
of HIF1a is associated with increased migration.
Greater HIF1a Expression Correlates with Increased Cell
Survival
One of the characteristics of CRPC is its resistance to chemo-
and radio-therapy. To investigate whether HIF1a is responsible
for the increased survival of CRPC-like cells in vitro, cell survival
following treatment of PC3 or LNCaP cells with two cytotoxic
agents, H2O2 (a source of oxidative stress) and 5-fluorouracil (5-
FU, a chemotherapeutic drug) was measured. Cell proliferation
assays (Figure 1D) revealed that the survival rates of 60614% and
4268% for PC3 cells following treatment with 100 mM H2O2 or
15 mM 5-FU respectively, were significantly greater than the
respective survival rates of 1764% and 361.6% in androgen-
sensitive LNCaP cells.
HIF1a Knockdown Decreases Cell Survival and Migration
of PC3 Cells
To confirm that the increased survival and migration of PC3
cells was due to greater HIF1a protein expression, the expression
of HIF1a in PC3 cells was knocked down using shRNA vectors.
Transfection of PC3 cells with a vector expressing HIF1a shRNA
reduced the HIF1a protein expression to 1263% in clone 1 and
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1663% in clone 2 compared to wild type PC3 cells (100%)
(Figure 2A). VEGF, a downstream product of HIF1a, was also
decreased in the HIF1a knockdown clones, confirming the
reduction in HIF1a activity (data not shown). The observation
that there was no difference in the basal proliferation rate between
HIF1a shRNA-expressing PC3 cells and PC3 cells transfected
with a scrambled control vector is consistent with the finding that
there was no correlation between greater HIF1a expression and
proliferation rate (Figure 1B). Following H2O2 treatment only
22.563% of the HIF1a knockdown PC3 cells (shRNA clone 1)
survived as compared to 58.5610% survival in scrambled control
vector-transfected PC3 cells (Figure 2B). Similarly, 5-FU reduced
the cell survival to 2762% in the HIF1a knockdown cells,
compared to 6269% cell survival in PC3 cells transfected with a
scrambled control vector. There was no significant change in the
expression of HIF1a following the treatment of PC3 cells
transfected with control shRNA with 100 mM H2O2 or 15 mM
5-FU as compared to untreated PC3 cells (Figure 2C). However
there were 2.360.2-fold and 6.661-fold increases in the expres-
sion of HIF1a following the treatment of PC3 cells with 1% O2 or
300 mM CoCl2, respectively (Figure 2C). As shown in Figure 2A
the basal expression of HIF1a in HIF1a shRNA expressing PC3
cells is undetectable, and therefore it is not feasible to determine
the effect of treatment with 100 mM H2O2 or 15 mM 5-FU on
HIF1a shRNA-expressing PC3 clones.
Previously a 1.8-fold greater migration rate was observed in
PC3 cells compared to androgen-sensitive LNCaP cells. To
determine whether or not this difference was mediated by HIF1a,
the migration of HIF1a knockdown and control vector transfect-
ed-PC3 cells was compared. Knockdown of HIF1a expression by
RNA interference decreased PC3 migration to 37610% (clone 1)
and 1467% (clone 2), compared to the control vector transfected-
PC3 cells (100%) (Figure 2D).
Induction of HIF1a in LNCaP Cells Increases Cell Survival
To determine whether induction of HIF1a expression in
androgen-sensitive LNCaP cells can increase their survival
following treatment with cytotoxic agents, HIF1a expression
Figure 1. Basal HIF1a protein expression, proliferation rates and migration/invasion rates in human PC cell lines. (A) Basal HIF1a
protein concentrations in the human PC cell lines LNCaP, DU145 and PC3 under normoxic conditions were analyzed by Western blot. (B) Proliferation
was assayed by cell counting after 24 and 48 hours. (C) Migration/invasion rates were measured by Transwell assays at 24 hours. Values in (A) and (C)
are expressed as the fold increase compared to LNCaP cells, while the values in (B) are expressed as a percentage of the time 0 value. All values are
the mean 6 SEM of at least three separate treatments. (D) Survival rates of PC cells exposed to cytotoxic conditions. The survival of PC3 cells (which
have higher basal HIF1a protein) when exposed to oxidative stress with hydrogen peroxide (H2O2) or chemotoxicity with 5-fluorouracil (5-FU) was
compared to the survival of LNCaP cells (which have lower HIF1a expression). Survival was assessed by counting cell numbers at 24 hours. Values are
expressed as a percentage of the untreated control and are the mean 6 SEM of at least three separate treatments. #, P,0.05 versus treated LNCaP
cells.
doi:10.1371/journal.pone.0054251.g001
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was induced using either hypoxia (1% O2) or the hypoxia
mimetic cobalt chloride (Figure 2E). Incubation of LNCaP cells
with either 100 mM H2O2 or 15 mM 5-FU reduced the survival
to 1764% and 2662% respectively compared to untreated
control (100%). However the survival rates in the presence of
100 mM H2O2 following the treatment of LNCaP cells with
either 1% O2 or cobalt chloride increased to 4068% and
49611% respectively. The survival (113623%) of LNCaP cells
treated with 300 mM CoCl2 in combination with 15 mM 5-FU
was significantly higher compared to the survival (54610%)
observed in LNCaP cells treated with 1% O2 in combination
with 15 mM 5-FU. Interestingly, 300 mM CoCl2 in combination
with 15 mM 5-FU induced a slightly higher 3.360.5-fold
increase in HIF1a expression in LNCaP cells as compared to
the 2.160.4-fold increase induced by 1% O2 in combination
with 15 mM 5-FU, although the difference was not statistically
significant (Figure 2F).
Figure 2. Knockdown of HIF1a expression in PC3 cells reduced both survival after cytotoxic treatments and migration rate. (A) HIF1a
concentrations were reduced in 2 separate clones of PC3 cells following stable expression of HIF1a shRNA as assessed by Western blot. Values are the
mean6 SEM of at least three separate experiments and are expressed as a percentage of wild-type PC3 cells. *, P,0.05 versus wild-type PC3 cells. (B)
The survival of PC3 cells after exposure to oxidative stress (hydrogen peroxide (H2O2)) or chemotoxicity (5-fluorouracil (5-FU) for 24 hours was
reduced following HIF1a knockdown compared to scrambled control vector-transfected PC3 cells. Values are the mean 6 SEM of at least three
separate experiments and are expressed as a percentage of untreated scrambled control vector-transfected PC3 cells. #, P,0.05 versus control. (C)
HIF1a protein expression in PC3 cells transfected with control shRNA after treatment with 1% O2, 300 mM CoCl2, 100 mM H2O2, and 15 mM 5-FU. Cell
lysates were electrophoresed on SDS-polyacrylamide gels and blotted with HIF1a antibody. GAPDH expression was used as loading control. The
Western blots shown are representative of at least three separate experiments. Band densities were determined by densitometric analysis of HIF1a/
GAPDH and are presented relative to the value for untreated cells. Data represent mean 6 SEM; * p,0.05 vs. untreated PC3 cells. (D) Rates of
migration/invasion in the HIF1a knockdown PC3 cells were reduced compared to the scrambled control vector-transfected PC3 cells as assessed by
Transwell assay. Values are the mean6 SEM of at least three separate experiments and are expressed as a percentage of untreated scrambled control
vector transfected PC3 cells. *, P,0.05 versus control. (E) Induction of HIF1a in LNCaP cells by hypoxia (dark grey bars) or by cobalt chloride (light grey
bars) increased survival after exposure to oxidative stress with H2O2 or chemotoxicity with 5-FU for 24 hours when compared to control LNCaP cells
(black bars). Values are the mean 6 SEM of at least three separate treatments and are expressed as a percentage of the untreated LNCaP control. #,
P,0.05 versus treated LNCaP cells. *, P,0.05 versus LNCaP cells treated with 1% O2 and 5-FU. (F) HIF1a protein expression in LNCaP cells treated with
1% O2 and 300 mM CoCl2 in combination with either 100 mM H2O2 or 15 mM 5-FU. Cell lysates were electrophoresed on SDS-polyacrylamide gels and
blotted with HIF1a antibody. GAPDH expression was used as loading control. The Western blots shown are representative of at least three separate
experiments. Band densities were determined by densitometric analysis of HIF1a/GAPDH and are presented relative to the value for normoxic cells
undergoing the same treatment. Data represent mean 6 SEM; * p,0.05 vs. untreated control, 100 mM H2O2 or 15 mM 5-FU treated LNCaP cells.
doi:10.1371/journal.pone.0054251.g002
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Increased Translation Efficiency of HIF1a mRNA is
Responsible for HIF1a Overexpression in PC3 Cells
Although the regulation of translation by the 59UTR is a major
mechanism for post-transcriptional regulation of gene expression,
the translation efficiency of HIF1a mRNA in prostate cells has not
been reported previously. As shown in Figure 3A the ratio of Firefly
to Renilla luciferase activity following the transfection of HIF1a
59UTR-LUC reporter and pTK-Renilla control vectors was
2063-fold and 2663-fold in LNCaP and PC3 cells, respectively,
compared to cells transfected with the empty pGL4 vector.
However luciferase mRNA expression was 3361.4-fold in LNCaP
and 962.1-fold in PC3 cells compared to empty pGL4 vector-
transfected cells (Figure 3B). Further the translation efficiency of
HIF1a mRNA in PC3 cells was 2.960.4-fold higher compared to
LNCaP cells when evaluated using the index of luciferase activity/
relative mRNA content (Figure 3C).
HIF1a Protein Expression in Human Prostate Cancer
Tumors
One hundred human PC specimens were divided into two
groups according to their Gleason score (#7 (38) and .7 (62),
Table 1) and HIF1a status. The expression of HIF1a was assessed
by immunohistochemistry (Figure 4A). Figure 4A (a) shows a
positive, and Figure 4A (b) shows a negative, HIF1a staining in
two typical tumors with Gleason score 9 (Inset box, X20 view).
Figure 4A (c) demonstrates a positive, and Figure 4A (d)
demonstrates a negative (d), HIF1a staining in two typical tumors
with Gleason score 6. Positive staining in PC3 cells (Figure 4A (e))
and negative staining in LNCaP cells (Figure 4A (f)) and in HIF1a
knockdown PC3 cells (Figure 4A (g)) demonstrated the specificity
of the HIF1a antibody. Additionally, HIF1a was expressed
throughout the tumor with increased expression in the main
prostatic glands (indicated by the arrow in Figure 4A (a)) and in
lymph node metastases (indicated by the arrow in Figure 4A (h)).
In positive specimens HIF1a expression was homogeneous
throughout the tumor area.
HIF1a positivity rates (76% and 87%) were similar between the
Gleason groups (Table 1). Despite finding higher numbers of T3-
T4 stage tumors that expressed HIF1a (78%) compared with T1-
T2 stage tumors (21%), there was no significant association
between HIF1a positivity and higher stage (T3-T4) tumors or
Gleason scores (Table 1). 43 patients with tumors with Gleason
score .7 were started on ADT. Notably, of the 23 patients who
progressed to CRPC, 7 patients who were treated with chemo-
therapy developed resistance and all these patients were HIF1a
positive.
HIF1a as a Predictor for Progression to Metastatic PC,
Development of CRPC, and Prostate Cancer-specific
Death in Patients Who Commenced ADT
Metastasis-free survival was significantly decreased in patients
whose tumors expressed HIF1a. CRPC-free survival was also
significantly decreased in patients who were started on ADT as
demonstrated by Kaplan-Meier curves and Log Rank test.
Although prostate cancer-specific survival was also decreased,
the differences were not statistically significant (Figure 4).
The tumors of 27 patients who progressed to metastases out of
the total of 87 patients, and the tumors of 23 patients who
developed CRPC out of the total of 43 patients on ADT,
expressed HIF1a (Table 2). HIF1a and Gleason score were
independent risk factors for development of metastases on a Cox
regression analysis. Although all patients who developed CRPC
while on ADT had higher Gleason scores, the expression of HIF1a
was an independent risk factor for developing castrate resistance as
determined by Univariate and Multivariate Cox regression
analysis (Table 2). Furthermore, patients with tumors that were
positive for HIF1a were at a 10-fold higher risk of developing
castrate resistance (p = 0.021) and 9.8-fold higher risk of progress-
ing to metastatic prostate cancer (p = 0.017) than patients not
expressing HIF1a. Although patients whose tumors expressed
HIF1a had a higher risk of PC-specific death, this difference was
not statistically significant possibly due to the small sample size. In
addition, 4 samples of lymph node metastatic tissue and 2 samples
of distant metastatic tissue (1 bony metastasis and 1 lung
metastasis) expressed HIF1a. Examination of the lymph node
Figure 3. The translation efficiency of the HIF1a 59UTR-
luciferase reporter in prostate cancer cells. (A) Firefly and Renilla
luciferase activities in prostate cancer cells following transfection of a
HIF1a 59UTR-luciferase construct and the pTK-Renilla control reporter
vector were determined using a dual luciferase assay. (B) Real-time PCR
(RT-PCR) analysis of luciferase mRNA in PC cells transfected with the
HIF1a 59UTR-luciferase construct. Following transfection, RNA was
isolated, and luciferase mRNA expression detected by real time RT-PCR
and normalized by 18S mRNA expression. (C) Translational efficiency
represents the ratio of Firefly/Renilla luciferase activity, divided by the
relative luciferase mRNA concentration in PC cells. The translational
efficiency of luciferase mRNA driven by the 59UTR region of HIF1a in
PC3 cells is higher than in LNCaP cells. Values are the mean6 SEM of at
least three separate experiments. *, P,0.05 versus treated LNCaP cells.
doi:10.1371/journal.pone.0054251.g003
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tissue (Figure 4A (h)) revealed that HIF1a was expressed in the
tumor deposits, further demonstrating that the tumors cells over-
expressing HIF1a metastasize in agreement with our in vitro data.
Diagnostic Accuracy of HIF1a
Given the high risk of progression to metastases and of
development of CRPC and prostate cancer-specific death, the
diagnostic accuracy of HIF1a in determining these outcomes was
analyzed. The absence of HIF1a was highly sensitive (all 100%)
with very good positive predictive values (all 100%) for a favorable
prognosis in the 3 outcomes. These observations suggest that the
absence of HIF1a may have potential value as a predictor of men
who are unlikely to progress to metastases and develop CRPC.
Discussion
The data presented herein indicate that HIF1a is an
independent risk factor for the development of CRPC. HIF1a
expression was independent of Gleason score, tumor stage or type
of treatment received. The multivariate analysis revealed that the
risk of developing CRPC in the ADT-treated patients whose
tumors expressed HIF1a increased by 10-fold. This observation
clearly indicates the importance of assessing HIF1a status, which
can be used to predict those patients who will develop CRPC and/
or be candidates for early use of emerging second-line hormonal
therapies.
The significance of the expression of HIF1a in prostate tumors
has been investigated previously. Vergis and co-workers recently
reported a significant association between cytoplasmic HIF1a
levels in prostate tumors and time to biochemical recurrence in a
cohort of prostate cancer patients treated with radiotherapy or
Figure 4. Kaplan–Meier Estimates of CRPC-free survival, metastasis-free survival and prostate cancer specific survival in patients.
(A) Representative immunohistochemistry results showing expression of HIF1a in prostate cancer specimens and cell lines. Positive (Aa) and negative
(Ab) staining for HIF1a was observed in two typical tumors with Gleason score 9 (Inset box, X20 view). Positive (Ac) and negative (Ad) staining was
also observed in two typical tumors with Gleason score 6. Positive staining in PC3 cells (Ae) and negative staining in LNCaP cells (Af) and in HIF1a
knockdown PC3 cells (Ag) demonstrated the specificity of the HIF1a antibody. Additionally, HIF1a was expressed throughout the tumor with
increased expression in the main prostatic glands (indicated by the arrow in Aa) and in lymph node metastases (indicated by the arrow in Ah). (B) The
Kaplan–Meier survival curve demonstrates the metastasis–free survival versus the time from surgery. (C) The Kaplan–Meier survival curve
demonstrates the CRPC- free survival versus the time from the start of androgen deprivation therapy. (D) The Kaplan–Meier survival curve
demonstrates the prostate cancer specific survival versus the time from the start of androgen deprivation therapy. None of the HIF1a negative
patients had any of the adverse outcomes in (B), (C) or (D). Outcome was analyzed by Log Rank (Mantel – Cox) tests.
doi:10.1371/journal.pone.0054251.g004
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Table 1. Patient characteristics for the groups with Gleason score #7 or .7 and differences in HIF1a expression between the
groups.
HIF1a positive HIF1a negative
Gleason score #7 Gleason score .7 Gleason score #7 Gleason score .7
Number of patients 29 54 9 8
Mean age (years) 59.9 70.7 62.2 68.1
Tumor Stage (T1–T2) 23 9{ 8 3{
Tumor Stage (T3–T4¥) 6 29{ 1 4{
Median pre-interventional PSA* 6.4 (1.4 – 43) 14 (0.7 – 483.7) 5.4 (4 – 10.2) 14.8 (2 – 40.2)
Median follow-up from diagnosis
in years
2.3 3.6 2.4 3.3
Patients started on androgen
deprivation therapy¥
0 38 0 5
The group with Gleason score #7 was comprised of Gleason score ,6 (6), 6 (28) and 7 (4) and the group with Gleason score .7 was comprised of scores 8 (8), 9 (52)
and 10 (2).
{There were 17 patients with missing data for tumor stage in the group with Gleason score .7 and 16 of these patients were HIF1a positive.
¥There was no significant association with HIF1a expression and Gleason scores when analyzed using Pearson’s Chi-squared test or Fisher’s exact test using two-by-two
tables.
*Pre-interventional PSA was defined as PSA immediately prior to obtaining the tissue sample.
doi:10.1371/journal.pone.0054251.t001
Table 2. Univariate and Multivariate Cox Regression analysis of the development of metastatic PC from the time of surgery and
CRPC, prostate cancer specific death after starting androgen deprivation therapy.
No. of patients with
event Univariate analysis Multivariate analysis
Relative Risk (95% CI) P value Relative Risk (95% CI) P value
Progression to metastatic PC (n =87a) 27
HIF1a status
HIF1a negative 0 1.0{ 1.0{
HIF1a positive 27 10.7 (4.5–‘) 0.011 9.8 (3.9–‘) 0.017
Gleason score{
Gleason #7 1 1.0{ 1.0{
Gleason .7 26 6.9 (5.8–‘) 0.002 10.7 (9.7–‘) 0.001
Age 1.1(1.0–1.1) 0.013 1.0 (1.0–1.1) 0.17
Pre-interventional PSA* 1.0 (0.99–1.00) 1.0 (1.0–1.0) 0.66
Development of CRPC in patients on ADT
(n=43)
23
HIF1a status{
HIF1a negative 0 1.0{ 1.0{
HIF1a positive 23 8.3 (3.1–‘) 0.03 10.0 (4.0–‘) 0.021
Age 1.0 (1.0–1.1) 0.404 1.0 (0.9–1.0) 0.448
Pre-interventional PSA* 1.0 (1.0–1.0) 0.349 1.0 (1.0–1.0) 0.836
PC specific deaths in patients on ADT (n=43)13
HIF1a status{
HIF1a negative 0 1.0{ 1.0{
HIF1a positive 13 5.7 (2.1–‘) 0.111 3.07 (1.5–‘) 0.36
Age 1.1 (1.0–1.1) 0.014 1.1(1.0–1.2) 0.38
Pre-interventional PSA* 1.0 (0.9–1.0) 0.270 1.0 (1.0–1.0) 0.78
a13 patients excluded due to incomplete metastasis related data.
{Cox regression with Firth’s penalized maximum likelihood method. CI denotes confidence interval.
{This group served as the reference group in the Cox regression analysis.
*Pre-interventional PSA was defined as PSA immediately prior to obtaining the tissue sample.
doi:10.1371/journal.pone.0054251.t002
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radical prostatectomy [27], while Yasuda and co-workers demon-
strated that HIF1a expression increases relative risk of recurrence
of prostate adenocarcinoma [31]. However, some studies have
failed to demonstrate a significant correlation between accumu-
lation of nuclear HIF1a in prostate tumors and PSA recurrence
[32], [25]. In one such study, HIF1a expression showed no
correlation with the therapeutic effects of neo-adjuvant hormone
therapy post radical prostatectomy in prostate adenocarcinoma,
although it was hypothesized that HIF1a might be a useful
biomarker for predicting early castration resistance with hormone
therapy [31]. That hypothesis has now been verified in our study.
Although Gravdal and co-workers had demonstrated that
castration-resistant cancers have increased HIF1a expression
[26], to our knowledge no previous studies have looked at the
correlation between normoxic expression of HIF1a and develop-
ment of CRPC. Dai and co-workers have demonstrated that
hypoxia-mediated HIF1a expression increases invasiveness in PC
cell lines [16]. However, the effects of normoxic HIF1a expression
in PC cells had not been investigated prior to our study. Our
results demonstrate that normoxic expression of HIF1a results in
high invasion and chemo-resistance similar to hypoxia-induced
expression of HIF1a,
Furthermore, our study suggests the possible use of HIF1a
expression as a better screening tool for the development of CRPC
than other biomarkers of CRPC such as chromogranin A (CgA)
[3] or circulating tumor cells [33], because of its high sensitivity
and negative predictive value. Although no HIF1a expression was
seen in normal prostatic tissue, the HIF1a protein expression seen
in benign prostatic hyperplasia (BPH) and prostatic intra-epithelial
neoplasia (PIN) results in poor specificity [24], [18]. HIF1a
expression in our study was analyzed in tissue from TURPs as well
as radical prostatectomy tissue, and HIF1a expression analysis can
also be performed on needle prostate biopsies [31]. Therefore we
are currently performing a prospective study to evaluate the utility
of measurement of HIF1a expression in predicting the develop-
ment of CRPC.
The data presented herein also confirm that Gleason score is an
independent risk factor for developing CRPC. Although tumors
with higher Gleason score were associated with a shorter time to
development of CRPC among patients with metastatic disease
[34], a greater Gleason score was not consistently associated with
decreased survival in patients with metastatic disease starting ADT
[35], [36]. This effect is also seen in our study where the HIF1a
status is a better predictor of CRPC than Gleason score.
One of the possible mechanisms of castration resistance is the
activation of alternate growth-promoting pathways (including
those stimulated by IGF-1, EGF and HER2), which can drive the
growth of PC tumors independently of androgens [37]. Increased
HIF1a may facilitate the activation of alternate growth factor
pathways that circumvent therapeutic attempts to control the
growth of PC tumors by androgen ablation. Furthermore, the
observation that HIF1a can increase AR transactivation and
activate the AR signaling pathway [38] raises the possibility that
HIF1a-mediated AR signaling may be another mechanism by
which CRPCs grow in a low androgen environment. Given the
good outcomes in HIF1a negative tumors, HIF1a expression may
therefore be a characteristic phenotype of aggressive CRPC and
hence HIF1a may be a molecular target for treatment of CRPC.
CRPCs are chemo-resistant, with poor response to docetaxcel
[39]. Our in vitro results confirmed the chemo-resistant effects of
HIF1a in CRPC, as knockdown of HIF1a in PC3 cells increased
the sensitivity to cytotoxic treatments including oxidative stress
and 5-fluorouracil. In contrast, overexpression of HIF1a in
LNCaP cells increased the chemo-resistance to cytotoxic treat-
ments. Our results are consistent with previous reports that high
levels of HIF1a reduced the effectiveness of cytotoxic agents in
lung and gastric cancer cell lines [40], [41], [42]. Some
hypothetical mechanisms for chemo-resistance include inhibition
of drug efflux, autophagy, DNA repair, and apoptosis influenced
by genes directly or indirectly regulated by HIF1a [42], [43].
However further studies are required to elucidate the mechanism
of HIF1a-dependent chemo-resistance in CRPC-like cells and
tumors.
Nearly a decade ago, Zhong and co-workers discovered that
growth factor-stimulated activity of the phosphatidylinositol 3-
kinase (PI3K) pathway is responsible for the oxygen-independent
constitutive overexpression of the HIF1a protein in PC3 cells [14],
[23]. Although several different hypothesis have been raised to
explain the overexpression of HIF1a in PC tumors and cell lines,
including gene amplification [44], increased transcription of
HIF1a mRNA [45], single nucleotide polymorphisms [46],
expression of truncated HIF1a isoforms [19], and tumor
hypoxia-dependent stabilization of HIF1a [29], there is no
definitive consensus on the mechanism involved. Previously
HER2 signaling in non-hypoxic MCF-7 breast cancer cells has
been shown not only to affect HIF1a stability but also to increase
dramatically the rate of HIF1a protein synthesis [47]. Although
HIF1a signaling is upregulated in castration-resistant LNCaP C4-
2 cells as compared to the parental LNCaP cells [17] no previous
studies have compared the translation of HIF1a in androgen-
sensitive LNCaP and androgen-insensitive PC3 cells.
In the present study we therefore investigated the hypothesis
that increased translation of HIF1a mRNA is responsible for the
overexpression of HIF1a protein in CRPC-like cells. Transcrip-
tion of luciferase mRNA is 3-fold greater in LNCaP compared to
PC3 cells but, after correction for the transfection efficiency of the
HIF1a-Luc reporter construct, our results demonstrate for the first
time that there is a 3-fold increase in the translational efficiency of
HIF1a mRNA in PC3 cells compared to LNCaP cells. The
alternative explanation that the luciferase protein is 3-fold less
stable in LNCaP cells is less likely as the use of luciferase as a
reporter is based on the fact that its half life is similar in a range of
mammalian cells (tK , 3–4 hours, Promega). Mutation of the GC
rich region in the HIF1a promoter sequence has previously been
shown to decrease luciferase activity driven by the HIF1a
promoter [48], [49]. Interestingly we have noted that this GC-
rich region forms part of the 59UTR and not the promoter due to
a shift in the newly annotated transcription start site in the most
recent sequence of HIF1a mRNA in PubMed (NCBI Reference
Sequence: NM_001530.3) compared to the previously identified
transcription start site of the HIF1a gene [50]. The possibility that
the decrease in the luciferase activity observed by De Armond and
co-workers [49] may be due to a decrease in the translation rather
than transcription of luciferase mRNA deserves further attention.
Additional studies are also warranted to determine the role of the
GC-rich region and 59UTR in the increased translation of HIF1a
in prostate cancer cells, especially when enhanced protein
synthesis from a specific subset of mRNAs that contain highly
structured (GC-rich) 59UTRs is one of the hallmarks of cancer
[51], [52], [53]. In this context it is pertinent to note that a G-rich
oligonucleotide has been shown to inhibit HIF1a expression in
PC3 cells [54].
Previously hypoxia-induced HIF1a had been shown to increase
migration and chemo-resistance in PC cells [16]. In the current
study we have shown that normoxic HIF1a also increases
metastatic potential and chemo-resistance in PC cells and HIF1a
expressing human prostate tumors have poor outcomes. Although
expression of HIF1a was heterogeneous in tumor sections it would
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be difficult in the current study to predict whether up regulation of
HIF1a is hypoxia-dependent or -independent (normoxic). The
current paradigm is that tumor hypoxia increases HIF1a
expression in prostate cancer. Interestingly the expression of
HIF1a can also be increased under a normoxic environment at all
three levels of regulation (transcription, translation and protein
stability [55]) and overexpression of HIF1a under normoxia has
been detected in various cancers [56], [57], [58], [59]. Unlike the
case of melanoma where an increase in HIF1a expression under
normoxia is due to increased HIF1a protein stability [59], we have
shown that in PC cells the increase in HIF1a may be due to
increased HIF1a protein translation. The amount of HIF1a
mRNA in the metastatic advanced PC tumors is no different from
that in normal tissue [45] and therefore the possibility that in more
advanced metastatic CRPC tumors HIF1a expression is increased
via a translational mechanism rather a post-translational (oxygen-
dependent stability) or transcriptional pathway needs to be
investigated. Regardless of the hypoxic condition of the tumor,
therapeutic inhibition of HIF1a may be of use in the treatment of
metastatic prostate cancer. Furthermore a precise understanding
of the mechanisms behind the increased translation of HIF1a
protein in PC cells may not only lead to identification of novel
therapeutic targets to inhibit HIF1a expression, but may also
guide the choice of which HIF1a inhibitor from the many
available may work best in CRPC patients [60], [61].
Recently the cardiac glycoside digoxin has been shown to
inhibit HIF1a mRNA translation and PC3 tumor xenograft
growth in mice [62]. In a large prospective cohort study, Platz and
co-workers have demonstrated that men who used digoxin had a
25% lower risk of prostate cancer, including disease that was
potentially lethal [63]. A plausible explanation for these observa-
tions is that CRPC patients whose tumors express HIF1a are most
likely to respond favorably to digoxin in combination with
chemotherapy.
In conclusion HIF1a-positive tumors have a worse prognosis
compared to HIF1a-negative tumors. HIF1a expression is a better
indicator of PC-specific survival than Gleason score alone, and
could therefore be used to predict castrate resistance and hence
prognosis in tumors with high Gleason score. HIF1a expression in
CRPCs possibly contributes to chemo-resistance and tumor
metastasis. Although HIF1a inhibitors are currently being
evaluated in clinical trials for treatment of various tumors [13],
to our knowledge no trial is being conducted in CRPC. The
combination of HIF inhibitors with cytotoxic agents would seem
worthy of testing in CRPC. Targeted reduction of HIF1a may
increase the responsiveness of CRPCs to chemotherapy and thus
lead to better clinical prognosis and survival.
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